Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX).

Full DD Report for ACRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACRX)

60 Minutes to air piece on opioid drugmakers and distributors Sunday
CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden...
Source: SeekingAlpha
Date: December, 14 2018 13:50
AcelRx Pharmaceuticals to Present at Credit Suisse 27th Annual Healthcare Conference
REDWOOD CITY, Calif. , Nov. 7, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management w...
Source: PR Newswire
Date: November, 07 2018 17:19
Biotech Analysis Central Pharma News: Gilead's Push, AcelRx's Approval, Trevena's Rejection
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Gilead Sciences Makes Another Push Towards Immuno-Oncology News: Recently, Gilead Sciences ( GILD ) announced that it had formed a collaboration wi...
Source: SeekingAlpha
Date: November, 07 2018 14:58
AcelRx Pharmaceuticals, Inc. (ACRX) DSUVIA FDA Approval and AcelRx Third Quarter 2018 Conference Call (Transcript)
AcelRx Pharmaceuticals, Inc. (ACRX) DSUVIA FDA Approval and AcelRx Third Quarter 2018 Conference Call November 05, 2018 08:30 AM ET Executives John Saia - General Counsel Vince Angotti - CEO Dr. Pam Palmer - Chief Medical Officer Kimberley Gaumer - VP, Regulatory Affairs and Qu...
Source: SeekingAlpha
Date: November, 05 2018 14:40
Hopes Are High For AcelRx After Dsuvia Approval - Will Price Follow?
In the early afternoon on Friday, November 2, AcelRx's (NASDAQ: ACRX ) shares were halted by NASDAQ pending news from the company. Around an hour later, ACRX released a press release announcing that the company's lead drug candidate Dsuvia had been approved by the FDA for the treatment of a...
Source: SeekingAlpha
Date: November, 05 2018 11:00
Monday's Top Healthcare Stocks To Watch Ahead Of Elections
CORAL GABLES, FL / ACCESSWIRE / November 5, 2018 / It's no secret that technology has facilitated access and directly helped meet consumer needs in a multitude of industries. Healthcare has become the latest market to take full advantage of this trend. With the advent of technology in he...
Source: ACCESSWIRE IA
Date: November, 05 2018 11:00
Today's Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / AcelRx Pharmaceuticals saw big gains this past Friday after announcing third quarter results and an update on DSUVIA receiving FDA approval. Shares of Sage Therapeutics were halted after its treatment Zulresso, was recommended by an FDA approval...
Source: ACCESSWIRE IA
Date: November, 05 2018 08:00
AcelRx Pharmaceuticals misses by $0.01, misses on revenue
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q3 GAAP EPS of -$0.21 misses by $0.01 . Revenue of $0.37M (-75.2% Y/Y) misses by $0.72M . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 02 2018 16:09
AcelRx Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif. , Nov. 2, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today provided a business update and reported its third quarter 2018...
Source: PR Newswire
Date: November, 02 2018 16:05
AcelRx announces FDA approval of DSUVIA(TM)
REDWOOD CITY, Calif. , Nov. 2, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, announced today the approva...
Source: PR Newswire
Date: November, 02 2018 13:56

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-172.762.692.862.691,378,434
2018-12-142.832.772.942.751,452,590
2018-12-132.992.87843.04412.831,501,499
2018-12-123.182.9553.182.943,250,311
2018-12-113.323.143.403.102,278,191

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-17184,793414,58444.5731Short
2018-12-14292,110581,56050.2287Short
2018-12-13273,725442,33361.8821Short
2018-12-12604,8531,102,30554.8717Short
2018-12-11314,929645,45348.7919Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACRX.


About AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

Logo for AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $127,247,885 - 05/11/2018
  • Issue and Outstanding: 50,899,154 - 02/26/2018

 


Recent Filings from (NASDAQ: ACRX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 23 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 23 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 23 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018

 

 


Daily Technical Chart for (NASDAQ: ACRX)

Daily Technical Chart for (NASDAQ: ACRX)


Stay tuned for daily updates and more on (NASDAQ: ACRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ACRX and does not buy, sell, or trade any shares of ACRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/